Compass Therapeutics Investor Presentation Deck

Focused Pipeline with Multiple Value Inflection Points Lead Optimization IND Enabling Pre-Clinical Phase 1b Clinical Phase 2 Clinical Program CTX-009 CTX-471 CTX-8371 Undisclosed Target COMPASS THERAPEUTICS DLL4 x VEGF-A CD137 PD-1 x PD-L1 Autoimmune/ Oncology Discovery BTC Colorectal Ovarian / Other CD137 agonist (monotherapy) CD137 + PD-1 (combination)* Solid Tumors *Clinical collaboration with Merck & Co. Inc., Rahway NJ USA in combination with anti-PD-1 therapy KeytrudaⓇ C Next Milestone Initiate Phase 2/3 in U.S. Q1 2023 Top line data in U.S. Q3 2023 Initiate Phase 2 in U.S. H2 2023 Top line data in U.S. Q4 2023 Submit IND H1 2023 4

View entire presentation